ES2525376T3 - Composición farmacéutica comprendiendo amlodipino y ácido acetilsalicílico para uso en el tratamiento de hipertensión arterial sistémica - Google Patents
Composición farmacéutica comprendiendo amlodipino y ácido acetilsalicílico para uso en el tratamiento de hipertensión arterial sistémica Download PDFInfo
- Publication number
- ES2525376T3 ES2525376T3 ES06783799.7T ES06783799T ES2525376T3 ES 2525376 T3 ES2525376 T3 ES 2525376T3 ES 06783799 T ES06783799 T ES 06783799T ES 2525376 T3 ES2525376 T3 ES 2525376T3
- Authority
- ES
- Spain
- Prior art keywords
- arterial hypertension
- systemic arterial
- treatment
- acetylsalicylic acid
- amlodipine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037849 arterial hypertension Diseases 0.000 title abstract 3
- 230000009885 systemic effect Effects 0.000 title abstract 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001138 acetylsalicylic acid Drugs 0.000 title abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title 1
- 229960000528 amlodipine Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- 230000002744 anti-aggregatory effect Effects 0.000 abstract 2
- 239000003146 anticoagulant agent Substances 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 230000000302 ischemic effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 230000006441 vascular event Effects 0.000 abstract 2
- 208000001953 Hypotension Diseases 0.000 abstract 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 abstract 1
- 229960004005 amlodipine besylate Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención está relacionada con la industria farmacéutica en general y con la industria farmacéutica productora de medicamentos para el control de la hipertensión arterial sistémica yla prevención de eventos vasculares de origen isquémico en particular. Más específicamente se trata de una composición formada poruna sustancia hipotensora calcio antagonista en combinación conun agente antiagregante plaquetario. La composición se caracteriza en que dicha combinación o asociación consiste de una sustanciaseleccionada antagonista de los canales de calcio conocida comoAmlodipino besilato y una gente antiagregante plaquetario conocido como ácido acetilsalicílico; los cuales producen un producto con efecto sinérgico para el tratamiento de la hipertensión arterial sistémica y previene el riesgo de eventos vasculares de origenisquémico, con menores efectos secundarios.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA05014087 | 2005-12-20 | ||
| MXPA05014087A MXPA05014087A (es) | 2005-12-20 | 2005-12-20 | Composiciones farmaceuticas que comprenden sustancias calcio antagonistas combinadas con antiagregantes plaquetarios para su uso en hipertension arterial sistemica y la prevencion de eventos vasculares de origen isquemico. |
| PCT/MX2006/000069 WO2007073132A1 (es) | 2005-12-20 | 2006-07-12 | Composiciones farmacéuticas que comprenden sustancias calcioantagonistas combinadas con antiagregantes plaquetarios para su uso en hipertensión arterial sistémica y la prevención de eventos vasculares de origen isquemico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2525376T3 true ES2525376T3 (es) | 2014-12-23 |
Family
ID=38188837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06783799.7T Active ES2525376T3 (es) | 2005-12-20 | 2006-07-12 | Composición farmacéutica comprendiendo amlodipino y ácido acetilsalicílico para uso en el tratamiento de hipertensión arterial sistémica |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1964563B1 (es) |
| BR (1) | BRPI0620108A2 (es) |
| CR (1) | CR10104A (es) |
| CY (1) | CY1116068T1 (es) |
| EC (1) | ECSP088564A (es) |
| ES (1) | ES2525376T3 (es) |
| MX (1) | MXPA05014087A (es) |
| PL (1) | PL1964563T3 (es) |
| WO (1) | WO2007073132A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030099724A1 (en) * | 2001-11-16 | 2003-05-29 | Turner Oliver E. | Compounds for prevention of diabetic retinopathy |
-
2005
- 2005-12-20 MX MXPA05014087A patent/MXPA05014087A/es active IP Right Grant
-
2006
- 2006-07-12 ES ES06783799.7T patent/ES2525376T3/es active Active
- 2006-07-12 BR BRPI0620108-3A patent/BRPI0620108A2/pt not_active IP Right Cessation
- 2006-07-12 PL PL06783799T patent/PL1964563T3/pl unknown
- 2006-07-12 EP EP06783799.7A patent/EP1964563B1/en not_active Not-in-force
- 2006-07-12 WO PCT/MX2006/000069 patent/WO2007073132A1/es not_active Ceased
-
2008
- 2008-06-20 CR CR10104A patent/CR10104A/xx not_active Application Discontinuation
- 2008-06-20 EC EC2008008564A patent/ECSP088564A/es unknown
-
2014
- 2014-12-01 CY CY20141101002T patent/CY1116068T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1964563A1 (en) | 2008-09-03 |
| CY1116068T1 (el) | 2017-02-08 |
| WO2007073132A1 (es) | 2007-06-28 |
| MXPA05014087A (es) | 2007-06-20 |
| ECSP088564A (es) | 2008-07-30 |
| CR10104A (es) | 2008-08-21 |
| PL1964563T3 (pl) | 2015-05-29 |
| BRPI0620108A2 (pt) | 2011-11-01 |
| EP1964563B1 (en) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| PE20070420A1 (es) | Formulacion que contiene una combinacion de valsartan y amlodipina | |
| AR057181A1 (es) | Nueva forma de dosificacion de combinacion | |
| CY1121398T1 (el) | Συνδυασμος αδαπαλενης και υπεροξειδιου του βενζοϋλιου για την αγωγη των βλαβων της ακμης | |
| AR051397A1 (es) | Composicion farmaceutica | |
| CL2008000981A1 (es) | Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu | |
| BR112013009153A2 (pt) | formulação de ligante de fosfato para dosagem única. | |
| WO2007117706A3 (en) | Solid oral dosage form containing an enhancer | |
| UY32644A (es) | Compuesto anticancerígeno y composición farmacéutica que lo contiene | |
| PE20080658A1 (es) | Formulaciones de metilnaltrexona en forma de polvo seco | |
| UY32126A (es) | Composición farmacéutica sólida | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| ES2531516T3 (es) | Uso de escina | |
| DE602008006243D1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| ECSP099779A (es) | [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2h-quinazolina-3-ilo)-fenilo]-5-cloro tiofeno-2-ilo-sales de sulfonilurea, y las formas y métodos relacionados con el mismo | |
| CO6290623A2 (es) | Composicion efervescente que comprende una sal fisiologicamente aceptable de un amino acido basico, una fuente de acido y una sal de carbonato soluble | |
| ES2525376T3 (es) | Composición farmacéutica comprendiendo amlodipino y ácido acetilsalicílico para uso en el tratamiento de hipertensión arterial sistémica | |
| PE20081705A1 (es) | Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene | |
| AR050903A1 (es) | Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicos | |
| DE602006016785D1 (de) | Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung | |
| MX2008001532A (es) | Composicion farmaceutica que contiene indometacina y/o acemetacina. | |
| ATE439125T1 (de) | Fenofibrate tablett und verfahren zur herstellung | |
| ATE534382T1 (de) | Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon | |
| DE602006010397D1 (de) | Substituierte cyclohexanone | |
| AR067351A1 (es) | Combinacion de picotamida con nafronil |